Value of the Hepatic Venous Pressure Gradient to Monitor Drug Therapy for Portal Hypertension: A Meta-Analysis
- 1 May 2007
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 102 (5) , 1116-1126
Abstract
The use of the hepatic venous pressure gradient (HVPG) to assess the efficacy of the pharmacological treatment of portal hypertension in cirrhosis is controversial. Our aim was to establish whether target HVPG reduction predicts variceal bleeding in cirrhotic patients receiving variceal bleeding prophylaxis. Data sources were MEDLINE, EMBASE, Cochrane Controlled Trials Register, citation lists, and abstracts (most recent search March 2006). Cohorts of patients on drug therapy from randomized and nonrandomized studies correlating variceal bleeding and HVPG change were used. Heterogeneity was explored by metaregression analysis. Ten studies totaling 595 patients undergoing two HVPG measurements were identified. The RR of bleeding was lower in patients achieving an overall (HVPG ≤12 mmHg or decrease ≥20%) (0.27, 95% CI 0.14–0.52), complete (HVPG ≤12 mmHg) (0.48, CI 0.28–0.81), or partial (HVPG decrease ≥20%) (0.41, CI 0.20–0.81) response, with significant heterogeneity. Regression analysis identified the interval between the HVPG measurements significantly associated with the RR of bleeding. Heterogeneity was no longer significant after exclusion of an outlier trial, which showed the longest interval to HVPG remeasurement and the lowest quality score. Even considering nonevaluable patients because of bleeding as HVPG responders, the RR of bleeding was lower in overall responders than in nonresponders (0.66, CI 0.51–0.86). Overall response was associated with lower liver-related mortality (RR 0.58, CI 0.37–0.91). Current evidence supports the validity of HVPG end points to monitor drug therapy efficacy for variceal bleeding prophylaxis. HVPG monitoring also provides valuable prognostic information.Keywords
This publication has 32 references indexed in Scilit:
- The hepatic venous pressure gradient: Anything worth doing should be done rightHepatology, 2004
- The Hemodynamic Response to Medical Treatment of Portal Hypertension As A Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in CirrhosisHepatology, 2000
- Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertensionHepatology, 2000
- Pharmacological Treatment of Portal Hypertension: An Evidence-Based ApproachSeminars in Liver Disease, 1999
- Clinical vs haemodynamic response to drugs in portal hypertensionJournal of Hepatology, 1998
- Hepatic Venous Pressure Measurement: An Old Test As A New Prognostic Marker in Cirrhosis?Hepatology, 1997
- Nadolol plus Isosorbide Mononitrate Compared with Sclerotherapy for the Prevention of Variceal RebleedingNew England Journal of Medicine, 1996
- Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosisThe Lancet, 1995
- Beta-Adrenergic–Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal VaricesNew England Journal of Medicine, 1991
- Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhageGastroenterology, 1990